Composition for preventing or treating cellular senescence-associated diseases, containing homoharringtonine as active ingredient
The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising homoharringtonine as an active ingredient, and it was confirmed that the composition comprising homoharringtonine as an active ingredient exhibits a senolytics effect of selectively killing aging-induced fibroblasts and renal tubular cells, whereas aging-induced vascular endothelial cells and epithelial melanocytes and retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the homoharringtonine acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for whitening skin and life extension.
1. A method of treating a renal cell cancer and a renal fibrosis comprising administering a pharmaceutical composition comprising homoharringtonine as an active ingredient to a subject in need of the treating the renal cell cancer and the renal fibrosis,
wherein the renal cell cancer and the renal fibrosis are induced by a renal ischemia-reperfusion injury.
2. The method of claim 1 , wherein the homoharringtonine selectively kills a senescent cell or restores function or morphology of the senescent cell to a normal cell to treat the renal cell cancer and the renal fibrosis.
3. A method of treating peritoneal fibrosis comprising administering a pharmaceutical composition comprising homoharringtonine as an active ingredient to a subject in need of the treating the peritoneal fibrosis,
wherein the peritoneal fibrosis is induced by chlorhexidine gluconate.
4. The method of claim 3 , wherein the homoharringtonine selectively kills a senescent cell or restores function or morphology of the senescent cell to a normal cell to treat the peritoneal fibrosis.